Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target
BioAge Labs and Deep Origin announced a multi-target AI-driven drug discovery collaboration whose first milestone has been met: computationally identified small-molecule hits against a novel BioAge target were validated in BioAge's wet lab. Under the agreement, Deep Origin screens BioAge's selected targets using its DODock/DOScore virtual screening platform; BioAge validates hits, leads optimization, and drives clinical development, with Deep Origin eligible for success-based milestone payments. BioAge is advancing the first target into hit-to-lead optimization after Deep Origin delivered multiple structurally distinct hits in under three months.
Key figures
- Cd73 hit rate
- 30.6%
- Time to first hits
- less than three months
- Hit rate vs prior screen
- ~100x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.